Terbium161QualityChecker

Terbium-161

radiopharmaceuticals QC URS & FS input.csv output.json PET SPECT radiochemical purity
Open selection

Utility description: Terbium-161

Terbium-161 Quality Checker — Terbium-161 for targeted radionuclide therapy
ℹ️ Utility checks critical parameters of terbium-161:
• Radionuclidic purity (≥99.9%)
• Terbium-160 impurity (≤0.1%) — CRITICAL!
• Radiochemical purity (≥95%)
• Residual gadolinium (≤10 ppm) — affects labeling efficiency
• pH (1.0–2.5), endotoxins, sterility
⚠️ CRITICAL: Terbium-160 impurity >0.1% → chronic radiation burden (T½=72.3 days)!
Residual gadolinium >10 ppm → chelator competition and reduced product yield!
Usage:
Terbium161QualityChecker.exe → demo mode (console output)
Terbium161QualityChecker.exe input.csv output.json → evaluate your data
Input format:
BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Tb160ImpurityPercent,RadiochemicalPurityPercent,GadoliniumContentPPM,pH,EndotoxinsEU,SterilityTest,ProductType
Example (sterility: 0=sterile, 1=contaminated):
TB161-DOTA-2026-001,7500.0,99.95,0.02,98.5,2.5,1.8,45.0,0,DOTATATE
Supported product types:
• DOTATATE — therapy for neuroendocrine tumors (SSTR2+)
• PSMA — therapy for prostate cancer (PSMA+)
• FREECHLORIDE — precursor terbium-161 chloride
— WHY IS THIS NEEDED?
Terbium-161 is a promising "theranostic" isotope combining therapeutic and diagnostic properties:
• 6.89-day half-life — optimal for logistics and treatment
• Emits beta particles (for therapy) and conversion/Auger electrons (for destroying micrometastases)
• Ideal for peptide conjugates (DOTATATE, PSMA) due to short electron range
• Allows visualization of drug distribution (SPECT) due to gamma emission
⚠️ CRITICAL:
• Radionuclidic purity ≥99.9% — ensures absence of other radioactive isotopes
• Terbium-160 impurity ≤0.1% — CRITICAL! Tb-160 (T½=72.3 days) creates LONG-TERM RADIATION BURDEN to patient without therapeutic benefit. Requires strict control during production via Gd-160 irradiation.
• Residual gadolinium ≤10 ppm — CRITICAL! Gadolinium (target material for Tb-161 production) is chemically identical to terbium and competes for binding sites in chelators (DOTA). High Gd content reduces specific activity of the final product and delivery efficiency to the tumor.
• Radiochemical purity ≥95% — free Tb-161 accumulates in bones and liver, causing toxicity.
• pH 1.0–2.5 — critical for stability of terbium chloride solution (prevents hydrolysis and colloid formation).
• Endotoxins ≤175 EU/vial — critical for IV administration!
• Sterility — MANDATORY for all parenteral forms!
Key features:
• Check of critical terbium-160 impurity (≤0.1%) — main radionuclidic purity parameter
• Control of residual gadolinium (≤10 ppm) — unique parameter for Tb-161 affecting chemistry
• Support for different product types (DOTATATE, PSMA, free chloride)
• Specific pH limits for lanthanide ion stability
• Critical warnings about long-term radiation burden and chemical competition
Critical parameters:
• Radionuclidic purity: ≥99.9%
• Terbium-160 impurity: ≤0.1% (CRITICAL!)
• Radiochemical purity: ≥95.0%
• Residual gadolinium: ≤10.0 ppm (CRITICAL for labeling!)
• pH: 1.0–2.5
• Endotoxins: ≤175 EU/vial
• Sterility: no microbial growth
💡 Usage tips:
Terbium-160 impurity controlled by gamma spectrometry (peaks distinct from Tb-161).
Gadolinium content controlled by ICP-MS (Inductively Coupled Plasma Mass Spectrometry).
Radiochemical purity determined by TLC or HPLC with radio-detection.
For free terbium chloride, focus on radionuclidic purity and absence of gadolinium.
If Tb-160 impurity >0.1% or Gd >10 ppm detected — batch requires thorough review of purification technology.
⚠️ Note: Terbium-161 is considered an "ideal" successor to Lutetium-177 due to conversion electrons, which are more effective at destroying small clusters of tumor cells. However, the difficulty of separating Tb from the Gd target makes control of residual gadolinium a unique and critical parameter specifically for this isotope.

input.csv

BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Tb160ImpurityPercent,RadiochemicalPurityPercent,GadoliniumContentPPM,pH,EndotoxinsEU,SterilityTest,ProductType
TB161-TEST-001,5000.0,99.92,0.05,97.5,4.0,1.5,50.0,0,DOTATATE

URS & FS — User Requirements and Functional Specification

1. Scope

This document defines requirements and functional behaviour for Terbium161QualityChecker used to control: Terbium-161. The utility is intended for QC use and applies deterministic rules, not machine learning.

2. Execution modes

  • Terbium161QualityChecker.exe — demo mode or help output.
  • Terbium161QualityChecker.exe input.csv output.json — process user data and write result.

3. Key source-derived controls

  • ℹ️ Utility checks critical parameters of terbium-161:
  • • Radionuclidic purity (≥99.9%)
  • • Terbium-160 impurity (≤0.1%) — CRITICAL!
  • • Radiochemical purity (≥95%)
  • • Residual gadolinium (≤10 ppm) — affects labeling efficiency
  • • pH (1.0–2.5), endotoxins, sterility
  • ⚠️ CRITICAL: Terbium-160 impurity >0.1% → chronic radiation burden (T½=72.3 days)!
  • BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Tb160ImpurityPercent,RadiochemicalPurityPercent,GadoliniumContentPPM,pH,EndotoxinsEU,SterilityTest,ProductType
  • Example (sterility: 0=sterile, 1=contaminated):
  • ⚠️ CRITICAL:
  • • Radionuclidic purity ≥99.9% — ensures absence of other radioactive isotopes
  • • Terbium-160 impurity ≤0.1% — CRITICAL! Tb-160 (T½=72.3 days) creates LONG-TERM RADIATION BURDEN to patient without therapeutic benefit. Requires strict control during production via Gd-160 irradiation.
  • • Residual gadolinium ≤10 ppm — CRITICAL! Gadolinium (target material for Tb-161 production) is chemically identical to terbium and competes for binding sites in chelators (DOTA). High Gd content reduces specific activity of the final product and delivery efficiency to the tumor.
  • • Radiochemical purity ≥95% — free Tb-161 accumulates in bones and liver, causing toxicity.
  • • pH 1.0–2.5 — critical for stability of terbium chloride solution (prevents hydrolysis and colloid formation).
  • • Endotoxins ≤175 EU/vial — critical for IV administration!
  • • Sterility — MANDATORY for all parenteral forms!
  • • Check of critical terbium-160 impurity (≤0.1%) — main radionuclidic purity parameter
  • • Control of residual gadolinium (≤10 ppm) — unique parameter for Tb-161 affecting chemistry
  • • Specific pH limits for lanthanide ion stability

4. URS — user requirements

IDRequirementCriticalityAcceptance criterion
URS-001The utility shall accept input.csv with the exact headers defined in the data contract.HighThe file is processed without manual header changes.
URS-002The utility shall validate mandatory fields, data types, ranges, units, and critical pharmaceutical/radiochemical limits.HighEach row receives PASS/WARNING/FAIL status.
URS-003The utility shall detect critical deviations related to radionuclidic/radiochemical purity, impurities, free radionuclide, pH, endotoxins and sterility where such fields are present.HighA critical deviation produces FAIL or an explicit critical finding.
URS-004The utility shall generate output.json with machine-readable results, source values, warnings and failures.HighJSON is suitable for LIMS/ELN/MES integration and QA/QC review.
URS-005The utility shall not use machine learning to decide conformance.MediumThe decision is based on explicit rules and thresholds.
URS-006The utility shall preserve traceability between batch number, input values, applied rules and final status.HighThe output contains batch identifier and checked parameters.
URS-007The documentation shall support IQ/OQ preparation and inspection discussion with FDA/EMA/Roszdravnadzor or local regulator.MediumURS/FS and test scenarios are supplied with the utility.

5. input.csv contract

#FieldTypeSamplePurpose
1BatchNumberstringTB161-TEST-001Batch or lot identifier.
2ActivityMBqdecimal5000.0Activity of the radiopharmaceutical material or finished product.
3RadionuclidicPurityPercentstring99.92Radionuclidic purity; critical radiation safety attribute.
4Tb160ImpurityPercentstring0.05Controlled impurity; used in PASS/WARNING/FAIL decision logic.
5RadiochemicalPurityPercentstring97.5Radiochemical purity; verifies radionuclide binding and target chemical form.
6GadoliniumContentPPMdecimal4.0Controlled input parameter from input.csv.
7pHdecimal1.5Solution pH; stability and administration compatibility parameter.
8EndotoxinsEUdecimal50.0Bacterial endotoxins; critical criterion for parenteral administration.
9SterilityTestflag 0/10Sterility test result; 0 usually means no contamination.
10ProductTypestringDOTATATEProduct/radiopharmaceutical type; affects control interpretation.
BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Tb160ImpurityPercent,RadiochemicalPurityPercent,GadoliniumContentPPM,pH,EndotoxinsEU,SterilityTest,ProductType
TB161-TEST-001,5000.0,99.92,0.05,97.5,4.0,1.5,50.0,0,DOTATATE

6. FS — functional specification

IDFunctionImplementation
FS-001CSV importRead input.csv in UTF-8/CSV-compatible format; validate header and expected columns.
FS-002Schema validationValidate mandatory fields and column count; report unknown or missing key fields.
FS-003Type conversionConvert numeric, flag and text values; record invalid format as row-level error.
FS-004Rule engineApply domain rules for Terbium-161, including critical limits from the utility description.
FS-005Status aggregationGenerate final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance.
FS-006JSON exportWrite output.json with check details, source values, warnings and critical findings.
FS-007Audit supportKeep result structure suitable for review, deviation investigation and IQ/OQ preparation.

7. output.json example

{
  "utilityId": "terbium161-quality-checker",
  "api": "Terbium-161",
  "overallStatus": "PASS|WARNING|FAIL",
  "sourceFile": "input.csv",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "TB161-TEST-001",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "ActivityMBq",
      "value": "5000.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "RadionuclidicPurityPercent",
      "value": "99.92",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Tb160ImpurityPercent",
      "value": "0.05",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "RadiochemicalPurityPercent",
      "value": "97.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "GadoliniumContentPPM",
      "value": "4.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "pH",
      "value": "1.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "EndotoxinsEU",
      "value": "50.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    }
  ],
  "criticalFindings": []
}

8. OQ/PQ test scenarios

IDScenarioExpected result
OQ-001Valid sample rowPASS or acceptable WARNING according to rules.
OQ-002Mandatory column is missingSchema error or FAIL.
OQ-003Non-numeric value in numeric fieldType conversion error.
OQ-004Critical parameter outside limitFAIL and critical finding.
PQ-001User real batch/lotApproved review result with input.csv and output.json retained.

9. QA/QC and change control

  • Do not rename columns without validator update.
  • Store input.csv, output.json, executable version and checksum.
  • Before production use perform IQ/OQ/PQ or equivalent CSV/CSA verification.
  • Critical radiopharmaceutical limits must be checked against the approved specification and local SOPs.

Included in packages

Andrology QC Suite

QC package for andrology: androgens, erectile-dysfunction medicines, BPH/prostate products, fertility and related hormonal checks.

Open

Endocrinology QC Suite

QC package for endocrinology: thyroid, pituitary/peptide hormones, corticosteroids, sex hormones and selected metabolic medicines.

Open

Neurology QC Suite

QC package for neurology and neuropsychiatry: antiepileptics, antiparkinsonian medicines, antidepressants, antipsychotics, analgesics and neurological diagnostic radiopharmaceuticals.

Open

PetRad2: advanced radiopharmaceutical QC package

A curated set of new utilities for radionuclide control, targeted alpha therapy, specific activity, radiolysis stability and preliminary dosimetry calculations.

Open

Radiology QC Suite

QC package for radiology and diagnostic imaging: radiopharmaceuticals, PET/SPECT, contrast media, iodinated and gadolinium products, plus particle, sterility and endotoxin checks.

Open

RPH isotope family: beta-emitting therapy

Lu-177, Y-90, Ho-166, Re-188, Sm-153, Sr-89, P-32, Cu-67 and Tb-161.

Open

RPH organ/system: bone and musculoskeletal

Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.

Open

RPH organ/system: brain and CNS

Brain perfusion, dopamine transporter, amyloid/tau, receptor imaging and neurological SPECT/PET.

Open

RPH organ/system: endocrine, thyroid and NET

Radioiodine, thyroid/parathyroid, somatostatin receptor, MIBG and neuroendocrine workflows.

Open

RPH organ/system: hepatobiliary and GI

HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.

Open

RPH organ/system: oncology and theranostics

Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.

Open

RPH use case: radionuclide therapy and theranostics

Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.

Open

RPH workflow: generators and isotope purity

Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.

Open

RPH workflow: product release QC

Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.

Open

RPH workflow: stability, storage, decay and waste

Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.

Open

RPH workflow: synthesis, labelling and kit reconstitution

Radiolabelling, synthesis, chelation, reducing agent, pH/stoichiometry and kit preparation.

Open

RPH: combined radiopharmaceutical QC package

RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.

Open

Urology QC Suite

QC package for urology: BPH, urolithiasis, overactive bladder, urinary-tract infection medicines and supporting antimicrobial QC checks.

Open